Azacitidine for thrombocytopenia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Jul 2022: Trial registered, NCT05469737
  2. 14 Dec 2022: Trial started, NCT05469737

The trials

NCT05469737: A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

State
Under way
Phase
Phase 2 and Phase 3
People
230 planned
Started
14 Dec 2022
Primary completion
31 Jul 2028
Arms
Part I - Oral-Aza (Dose 1), Part I - Oral-Aza (Dose 2), Part II - Oral-Aza (RP3D)
Results
None posted
  1. 22 Jul 2022: Trial registered
  2. 14 Dec 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Onureg, Vidaza.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.